for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Diffusion Pharmaceuticals Inc

DFFN.OQ

Latest Trade

2.20USD

Change

0.07(+3.29%)

Volume

7,176

Today's Range

2.11

 - 

2.20

52 Week Range

1.84

 - 

10.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.13
Open
2.15
Volume
7,176
3M AVG Volume
1.81
Today's High
2.20
Today's Low
2.11
52 Week High
10.98
52 Week Low
1.84
Shares Out (MIL)
4.69
Market Cap (MIL)
10.00
Forward P/E
-0.76
Dividend (Yield %)
--

Latest Developments

More

Diffusion Pharmaceuticals Says Qtrly Loss Per Share $0.63

Diffusion Pharmaceuticals Reports Favorable Safety Data For Dose-Escalation Run-In

Diffusion Pharmaceuticals Announces $6.45 Million Registered Direct Offering & Private Placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Diffusion Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Industry

Biotechnology & Drugs

Contact Info

2020 Avon Ct Ste 4

+1.434.2200718

https://diffusionpharma.com/

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-29.682

2018

-8.374

2019(E)

-2.890
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-74.81
Return on Equity (TTM)
-72.16

Latest News

BRIEF-Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock

* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2nGHE9Q) Further company coverage:

BRIEF-Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering

* DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING

BRIEF-Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme

* DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME

BRIEF-Diffusion Pharma Files For Stock Offering For Up To About $15 Mln

* DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2BbtOBi) Further company coverage:

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up